The Drug Discovery for Neurodegeneration conference advances drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies.
The course is designed to give participants knowledge and relevant resources about this field of scientific investigation and address the associated barriers and challenges.
The program will focus on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.
|
|
COURSE OBJECTIVES
|
|
1. Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease
2. Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease
3. Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease
4. Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.
|
|
2011 MEETING SUMMARY
|
|
Click here to review the 2011 meeting summary along with session details, presentations, speakers, etc.
|
|
 |
|
WHAT YOU WILL LEARN
|
|
·
Fundamentals of medicinal chemistry for biologists
·
Basics
of high-throughput screening and assay development
·
Optimizing lead compounds and conducting in vivo efficacy
and safety studies
·
Utilizing animal models in preclinical development
·
Requirements for an Investigational New Drug (IND) application
·
Designing drugs for CNS target classes
·
Working efficiently with technology transfer offices
·
Intellectual property strategy: commercial potential,
protectability and patentability
·
Best
practices and lessons learned
·
Accessing resources and funding
|
|
SCIENTIFIC ADVISORY COMMITTEE
|
|
Kurt R. Brunden, PhD, University of Pennsylvania
Neil Buckholtz, PhD, National Institute on Aging
Rebecca Farkas, PhD, National Institute of Neurological Disorders and Stroke
Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation
Brian Fiske, PhD, Michael J. Fox Foundation for Parkinson’s Research
Mark Frasier, PhD, Michael J. Fox Foundation for Parkinson’s Research
Abram Goldfinger, MBA, New York University
Lorenzo Refolo, PhD, National Institute on Aging
Suzana Petanceska, PhD, National Institute on Aging
Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation
Edward G. Spack, PhD, Fast Forward, LLC
D. Martin Watterson, PhD, Northwestern University
|
|
|
|
TARGET
AUDIENCE |
|
 Academic and industry
scientists engaged in
drug discovery research
for neurodegenerative
disease or CNS
Business development
and licensing
professionals
Alliance management
professionals
Young investigators and graduate students |
|
ARCHIVED PROGRAMS
|
|
All pages will open in new windows:
|
|
The 2011 Drug Discovery for Neurodegeneration Conference presentations are available on demand. Click 
